Systemic lupus erythematosus (SLE) is a disease characterised by loss of B-cell tolerance to autoantigens, particularly nucleic acids and their binding proteins. Although autoantibodies to nuclear antigens are elicited in healthy individuals during protective immune responses (Ref. 1) and are present in the serum of up to 20% of the population, they are not sufficient to cause autoimmune disease. Clinical onset of SLE is often preceded by epitope spreading with development of antibodies to multiple nuclear antigens (Ref. 2) . In addition, recruitment of inflammatory cells and mediators to susceptible target organs is required. Multiple genetic pathways predispose to development of SLE, some of which are shared by other autoimmune diseases; usually there are contributions from three or more susceptibility alleles in individual patients (Ref. 3) . The disease may be triggered in genetically susceptible individuals by environmental factors, including microbial antigens, drugs, toxins and hormones. Because a single cause for SLE has not been identified, therapy has relied on global immunosuppression; however, this causes significant morbidity and mortality from unwanted side effects including infections, osteoporosis, infertility and premature atherosclerosis.
More than a hundred single genetic defects affecting the immune system cause SLE-like disease in mice ( Refs 3, 4, 5) , suggesting that there are many pathways that can be targeted therapeutically. The major challenge to assembling a new therapeutic armamentarium for SLE is the difficulty in conducting largescale clinical trials in this highly complex disease. In addition, because of the heterogeneity of the disease, targeting a particular immune pathway may not be equally successful for each patient. Furthermore, restoration of homeostasis may be difficult to achieve because insufficient or excessive cell activation can predispose to autoimmunity. For example, insufficient B-cell signalling can result in selection of autoreactive B cells into the naive B-cell repertoire (Ref. 6 ), whereas excessive B-cell signalling can result in the escape of autoreactive cells during antigenic stimulation (Ref. 7) . In addition, many inflammatory mediators have pleiotropic effects that are dependent on the microenvironment and the cell activation state. Finally, synergistic combinations of drugs that allow smaller doses and therefore less toxicity need to be identified.
The innate immune system as a target for SLE therapy
The innate immune system comprises cells and soluble molecules that are the first responders to an immune insult. Receptors on cells of the innate immune system recognise microbial components and induce cellular activation and cytokine release that induce activation and proliferation of T and B cells. The innate immune system is also crucial for noninflammatory clearance of apoptotic material generated from normal cell turnover. Circulating natural antibodies, complement and other acute-phase proteins opsonise and help specialised cells to clear foreign material. A defect in these functions can give rise to autoimmunity.
An emerging concept in the pathogenesis of SLE is that an excessive load of apoptotic particles containing nuclear antigens or of immune complexes containing autoantigens can overcome self-tolerance mechanisms and trigger autoimmunity (Refs 8, 9) . Loss of tolerance may be due to excessive generation of such material, deficiencies of circulating 'natural' IgM antibodies, complement and other proteins that are involved in opsonisation and clearance, or alterations in thresholds for signalling of the innate immune response (Refs 10, 11, 12, 13) . One mechanism for the pathogenicity of increased antigenic or apoptotic load is through activation of Toll-like receptors (TLRs) that recognise foreign and endogenous nucleic acids (Ref. 14) . Four TLRs -TLR3, TLR7, TLR8 and TLR9 -expressed predominantly by antigen-presenting cells (APCs) and B cells belong in this category (Ref. 15 ). There has been much focus recently on TLR9 (which recognises bacterial CpG-rich DNA) and TLR7 (which recognises viral single-stranded RNA), which are normally sequestered inside endosomes away from circulating endogenous nucleic acids (Refs 15, 16) . However, these endosomes are situated adjacent to phagosomes that take up apoptotic material. In addition, nucleic acids within immune complexes can be delivered to TLR-containing endosomes after cellular uptake via either cell-surface B-cell receptors (BCRs) or Fc receptors (Refs 17, 18) . Blockade of this process underlies the therapeutic effect of antimalarial drugs in SLE patients (Ref. 19) .
Stimulation of TLR7 and TLR9 leads to transcription of genes encoding interleukin 6 (IL-6), IL-12, tumour necrosis factor a (TNF-a), type I interferons (IFNs) and other innate immune effectors (Refs 20, 21, 22) (Fig. 1) Several other members of the CD28 -B7 family have been characterised. B and T lymphocyte attenuator (BTLA), like CTLA4 and PD-1, is a negative regulator of T-cell responses and its deficiency results in increased susceptibility to induced autoimmunity. BTLA is unusual because it binds herpesvirus entry mediator (HVEM), a member of the tumour necrosis factor receptor family (Refs 81, 82). B7-H3 and B7-H4 bind to unidentified receptors (Ref. 83) . Little is currently known about the role of these molecules in autoimmune disease pathogenesis; however, these molecules appear to have their effects only at low antigen doses.
The TNF -TNFR family
Multiple members of this family mediate costimulation of T cells and B cells, with 4-1BB, CD40L and B-cell activating factor (BAFF) being most relevant to SLE therapies.
4-1BB
The engagement of the T-cell costimulatory receptor 4-1BB (CD137) paradoxically prevents germinal centre formation in a T-cell-dependent fashion. In SLE-prone mice, three doses of an agonistic anti-4-1BB antibody confers prolonged inhibitory effects on autoantibody production starting 
Type I interferons

IL-10
IL-10 is increased in patients with active SLE and correlates with disease activity (Refs 181, 182). Although IL-10 is classically considered an anti-inflammatory cytokine, its role in SLE appears to be an inflammatory one. Interferon g IFN-g accelerates disease in SLE-prone NZB/W mice whereas treatment with anti-IFN-g is protective (Refs 188, 189 ). IFN-g -/ -MRL/lpr mice were also protected from early death with a reduction in the severity of glomerulonephritis. These studies highlight the importance of IFN-g in accelerating SLE development, presumably by increasing MHC expression and autoantigen presentation to otherwise quiescent nontolerant anti-self T cells, and also by promoting local immune and inflammatory processes (Ref. 190) . By contrast, results in STAT-4-and STAT-6-deficient SLEprone mice showed surprisingly that a decrease in IFN-g and an increase in IL-4 accelerated SLE nephritis even though autoantibody titres were diminished (Ref. 191) . This may be due to early regulatory effects of IFN-g on the development of Th17 effector cells. IL-17-secreting cells appear to be critical effector cells in rheumatoid arthritis and multiple sclerosis (Ref. 192 ), but very little is known as yet about the role of this cytokine in SLE.
The inflammatory process in SLE nephritis
Proliferative glomerulonephritis is the most severe form of SLE nephritis and is characterised by mesangial proliferation and infiltration of the kidney parenchyma by inflammatory cells. This process is initiated by deposition of antibodies in the renal glomeruli but it is increasingly recognised that this is not sufficient for renal inflammation to occur. In NZB/W SLE-prone mice deficient in activating Fc receptors, autoantibody and complement deposition in glomeruli do not result in renal damage (Ref. 193) . Subsequently it was shown that the important Fc-receptor-bearing cells are of haematopoietic origin and that circulating monocytes bearing the activating receptors are sufficient to restore disease (Ref. 194) . In SLE patients, polymorphisms of Fc receptors have been associated with the susceptibility to renal disease (Ref. 48 ). Other downstream effector pathways including chemokines and cell death molecules are also required to mediate kidney damage. By contrast, in the MRL/lpr model, interstitial inflammation can occur in the kidney without immune-complex deposition and in the absence of Fc receptors, perhaps indicating that endothelial activation is sufficient to initiate inflammatory cell migration into target organs in this mouse (Refs 195, 196) . A model for the effector pathways involved in renal inflammation is shown in Figure 3 . Microarray analysis of human SLE biopsies has shown considerable heterogeneity in gene expression between patients. Infiltration by B cells and myeloid cells was observed in some patients, as was evidence of fibrosis. As observed in peripheral blood specimens, some patients also had a type I IFN signature in the kidney (Ref. 197) .
Invasion of the glomerulus and the interstitium by inflammatory cells involves different chemokines and receptors. In particular, CCR2 and CCR5 mediate glomerular cell invasion whereas CCR1 mediates interstitial invasion (Refs 198, 199) . Studies of chemokine expression in the kidneys of NZB/W mice have shown that a limited panel of chemokines is expressed in the early stages of nephritis. The onset of proteinuria coincides with expression of CCR2 and CCR5 ligands and with infiltration and activation of
The events that lead to renal failure in systemic lupus erythematosus Figure 4 . Therapies for systemic lupus erythematosus depend on the stage of disease. The various stages of SLE consisting of a pre-disease period followed by flares and remissions, are associated with differences in the state of immune activation which may require different therapeutic approaches. expert reviews system and excessive immune responses in the activated immune system. For this reason, restoration of immune homeostasis in SLE patients poses many challenges. It is increasingly recognised that therapies for active disease, characterised by lymphoid cell proliferation and production of multiple inflammatory mediators, may need to be different from therapies that prevent disease flares or those that might eventually prevent disease onset in genetically predisposed individuals (Fig. 4) . Despite these difficulties, many new drugs are being developed for the treatment of SLE and clinical trials are in progress.
Preclinical testing of novel therapies in murine models
As discussed above, immune activation pathways involved in initiation of SLE may not always be the same as those that are pathogenic during the effector phase. Furthermore, inflammatory environments can alter signalling cascades or provide redundant survival signals. Because the clinical effects of new therapeutics may not always be predictable from in vitro studies or studies in non-autoimmune mice, it is important to test these drugs in preclinical models. Many different mouse models of SLE now exist (Refs 3, 4, 5) and several of these have been extensively characterised and used for therapeutic studies 
Clinical trials in human SLE
New agents for which the results of clinical trials have been published are shown in Table 2 . Most of these trials were Phase II studies and had insufficient statistical power to assess clinical efficacy. However, several large Phase III studies are now in progress and results can be expected in the next few years. The design of SLE clinical trials will be of crucial importance in determining optimal therapies for induction of disease remission and for maintenance of disease remission. Much thought is being given to recruitment of patient populations, disease activity measurements, disease response measurements, primary outcome measures and mechanistic analyses of immunological responses in treated patients. Most clinical trials now employ the BILAG, a scoring system that measures the severity of disease in individual organ systems. Some drugs are being tested in remission induction studies whereas others are being tested in 'time-to-flare' studies. The choice of design will depend on the expected mechanism of action of each drug. For example, blockade of inflammatory cytokines or depletion of whole cell populations would be expected to induce remission of active disease whereas therapies that prevent naive cell activation or modulate B-cell selection would be expected to have a preventive rather than a remission Published in abstract form only but included here because it is a large Phase III study. Abbreviations: BAFF, B-cell-activating factor belonging to the TNF family (also known as BLyS, B lymphocyte activator); BILAG, British Isles lupus assessment; SLE, systemic lupus erythematosus; TNF, tumour necrosis factor. expert reviews http://www.expertreviews.org/ in molecular medicine induction effect. Testing in preclinical models may help direct trial design for each new agent. The range of new drugs being developed reflects the global nature of the immune defects in SLE (Fig. 5) . Approaches include measures to decrease antigen load (DNase), measures to dampen the innate immune system (ODN and IFN-a blockade), drugs that antagonise activation of the acquired immune system (costimulatory blockade, modulation of BCR signals), blockade of the soluble mediators derived from the effector arm of the immune response (cytokine antagonists), protection of target organs from damage (chemokine inhibitors, complement inhibitors) and even depletion of whole cell populations (B-cell depletion, stem cell transplant). In addition, there are agents designed to specifically target autoreactive B cells through induction of antiidiotypic antibodies. The scope of this article does not allow discussion of all the new drugs being developed, but for a comprehensive review see Ref. 143 . The challenge will now be to determine at which stage of disease each reagent is most likely to be effective and which reagents will work together. Optimal therapy will also require continued research that will eventually allow identification of the underlying immune defect in each patient. The ultimate goal is to selectively correct deficits that contribute to autoimmunity without impacting protective immunity.
Interactions of the innate and acquired immune system amplify immune responses in systemic lupus erythematosus Tables  Table 1 . Common mouse models of systemic lupus erythematosus used for therapeutic studies. Table 2 . Therapeutic trials of novel agents for systemic lupus erythematosus. 
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